AnalystsEva Fortea VerdejoEva Fortea Verdejo's Stock Forecasts
AnalystsEva Fortea Verdejo
Sectors:
Industries:
Analyst Ranking
Bottom 15%
#4152 out of 4871 analysts
Average Return
-14.4%
Win Rate
44%4 out of 9
Risk vs Reward
Poor
Good
Eva Fortea Verdejo's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Kiniksa Pharmaceuticals International PLCKNSA | +37.70% | $20.08 | $27.65 | 2024-05-02 - 2025-05-02 | Strong Buy |
Iteos Therapeutics IncITOS | +13.43% | $6.85 | $7.77 | 2025-04-28 - 2025-05-02 | Strong Buy |
Iteos Therapeutics IncITOS | +9.51% | $7.10 | $7.77 | 2025-03-06 - 2025-05-02 | Strong Buy |
Iteos Therapeutics IncITOS | +7.62% | $7.22 | $7.77 | 2024-12-18 - 2025-05-02 | Strong Buy |
Eva Fortea Verdejo Analyst Color
Get additional color on Eva Fortea Verdejo's coverage of popular stocks
Eva Fortea Verdejo's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Iteos Therapeutics IncITOS | 4 | Strong Buy | $16.00 | +105.92% | Maintains | 4 days ago |
Bicara Therapeutics IncBCAX | 1 | Strong Sell | $8.00 | -44.83% | Initiates Coverage On | 16 days ago |
Xencor IncXNCR | 2 | Strong Buy | $33.00 | +193.07% | Maintains | 2 months ago |
Arcus Biosciences IncRCUS | 1 | Strong Buy | $29.00 | +217.98% | Initiates Coverage On | 7 months ago |
Kiniksa Pharmaceuticals International PLCKNSA | 1 | Strong Buy | $34.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.